NCT06009029Not yet recruitingPhase 2
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
A Multicenter, Single-arm, Prospective Study of SBRT Combined With Zimberelimab (GLS-010) in Patients With Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Source: ClinicalTrials.gov · Last updated 24 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- First submitted
- 9 Aug 2023
- Start date
- Aug 2023
- Primary completion date
- Jul 2026
- Lead sponsor
- Peking University Third Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06009029
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 96
- From Aug 2023 to the primary completion date, Jul 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
- Contraindications to immunotherapy.
Other illness
- Has a known additional malignancy within the past 5 years, except for cured skin cancer and cervical carcinoma in situ.
- Other conditions that investigator decides not suitable for the trial.
Other
- Tumor invasion of the gastrointestinal tract, specifically pancreatic tumor or lymph node metastasis invading the gastrointestinal parenchyma.
- Woman who are pregnant or breastfeeding.
Who the study is looking for
- 18-75 years old.
- Locally advanced pancreatic cancer confirmed histologically and defined according to the NCCN Pancreatic Cancer Guidelines v1.2022 as unresectable or surgically declined.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- The expected survival ≥ 3 months.
- At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.
- Patient must have adequate organ function defined by the study-specified laboratory tests.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.